CA Patent

CA2840591A1 — Methods of administering 3,4-diaminopyridine

Assigned to Biomarin Pharmaceutical Inc · Expires 2013-01-03 · 13y expired

What this patent protects

Provided herein are methods of determining NAT acetylation status of a subject with a 3,4- DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminop…

USPTO Abstract

Provided herein are methods of determining NAT acetylation status of a subject with a 3,4- DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.

Drugs covered by this patent

Patent Metadata

Patent number
CA2840591A1
Jurisdiction
CA
Classification
—
Expires
2013-01-03
Drug substance claim
No
Drug product claim
No
Assignee
Biomarin Pharmaceutical Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.